Objectives
To assess the potential of second-generation proteasome inhibition by carfilzomib and its combination with the human immunodeficiency virus (HIV) protease inhibitors (HIV-PIs) lopinavir and nelfinavir in vitro for improved treatment of clear cell renal cell cancer (ccRCC).
Materials and Methods
Cytotoxicity, reactive oxygen species (ROS) production, and unfolded protein response (UPR) activation of proteasome inhibitors, HIV-PIs, and their combination were assessed in three cell lines and primary cells derived from three ccRCC tumours by MTS assay, flow cytometry, quantitative reverse transcriptase-polymerase chain reaction and western blot, respectively. Proteasome activity was determined by activity based probes. Flow cytometry was used to assess apoptosis by annexin V/propidium iodide assay and ATP-binding cassette sub-family B member 1 (ABCB1) activity by MitoTracker TM Green FM efflux assay (Thermo Fisher Scientific, MA, USA).
Results
Lopinavir and nelfinavir significantly increased the cytotoxic effect of carfilzomib in all cell lines and primary cells. ABCB1 efflux pump inhibition, induction of ROS production, and UPR pre-activation by lopinavir were identified as underlying mechanisms of this strong synergistic effect. Combined treatment led to unresolved protein stress, increased activation of pro-apoptotic UPR pathway, and a significant increase in apoptosis.
Introduction
During the last decade, several agents targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor receptor (PDGFR) and mammalian target of rapamycin (mTOR) pathways prevailed as novel standard of care in the treatment of metastatic RCC (mRCC) [1] [2] [3] . These 'targeted drugs' led to improved efficacy and reduced treatment-associated toxic effects compared to previous 'immunotherapy'. However, durable complete responses still remain the exception, survival rates of mRCC remain devastating and Grade 3 or 4 adverse events are still expected in one-third of patients [4] [5] [6] . Thus, despite ongoing improvement of mRCC therapy including nivolumab and cabozantinib, which were recently recommended for refractory clear cell RCC (ccRCC) due to a survival benefit in this setting [1, 2, 7] , evaluation of novel drugs for the treatment of mRCC seems to be mandatory [8] .
Pathogenesis and progression of RCC is particularly driven by hypoxia-inducible factor 1a (HIF-1a), which acts as a transcription factor for genes that are involved in angiogenesis, tumour cell proliferation, cell survival, and metastatic spread [9, 10] . Proteasome inhibitors have been shown to have a pro-apoptotic, anti-angiogenic and antiproliferative effect and to specifically inhibit activation of the C-terminal transactivation domain of HIF-1a, implicating their use in RCC treatment [11, 12] .
More than a decade ago, the first generation proteasome inhibitor bortezomib showed antitumour activity in individual patients with mRCC. However, in particular, neurotoxicity of bortezomib at the aspired dose of 1.5 mg/m 2 and subsequent dose reductions in most patients limited the use of bortezomib in patients with RCC [13] .
Concepts to improve proteasome inhibitor-based cancer therapies have since emerged. Compared to bortezomib, second generation proteasome inhibitors, like carfilzomib or ixazomib, show more selective binding to the b5 subunit of the proteasome. Thus, carfilzomib showed superiority over bortezomib on both efficacy and toxicity profiles (especially as it lacks neurotoxicity) and has been approved for the treatment of relapsed multiple myeloma in the USA since 2012 [14, 15] .
The unfolded protein response (UPR) prevents accumulation of misfolded and dysfunctional proteins in the endoplasmic reticulum (ER) by modulating mRNA translation, protein folding, and ultimately by protein destruction [16] . The proteasome is the terminal protease of this ER-associated degradation (ERAD) pathway. Sensitivity to proteasome inhibition is directly correlated to the activation status of the UPR, as well as to expression levels of the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1) a major regulatory switch of the UPR in multiple myeloma. Treatment with HIV protease inhibitors (HIV-PIs), like lopinavir or nelfinavir, induces IRE1/XBP1 expression and UPR activation in vivo [17] . The combination of HIV-PIs with proteasome inhibitors significantly sensitised myeloma cells to proteasome inhibitor treatment and overcame proteasome inhibitor resistance in vitro and in a clinical phase I trial [17, 18] . Thus, the combination of the second generation proteasome inhibitor carfilzomib with HIV-PIs may substantially increase the activity of proteasome inhibition also in RCC treatment.
Materials and Methods

Cell Lines
Caki-2, A498 and MZ1774 cell lines were obtained from commercial sources (American Type Culture Collection, ATCC; Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ) and were maintained under standard conditions in Roswell Park Memorial Institute (RPMI)-1640 medium (SigmaAldrich, St Louis, MO, USA) supplemented with 10% heatinactivated fetal bovine serum (FBS), 100 lg/mL streptomycin and 100 U/mL penicillin (Sigma-Aldrich). All cell lines were passaged under 20 times, routinely tested for mycoplasma contamination and authenticated by short tandem repeat (STR) profiling.
Tissue Samples and Primary Cells
Tissue specimens were obtained during standard surgical procedure of patients diagnosed with RCC who underwent surgery at the University Hospital Brno, Czech Republic. Written informed consent was obtained from all patients and the research project was approved by the University Hospital Brno Ethical Committee. Patient and tumour characteristics are described in Table S1 . Mechanical disaggregation of tumour specimen was used to obtain viable tumour cells, which were subsequently cultivated in Dulbecco's modified Eagle's medium (DMEM) containing high glucose, L-glutamine (GlutaMAX) and sodium pyruvate (Gibco/Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 19 non-essential amino acids (Gibco/Thermo Fisher Scientific), 20% heatinactivated FBS, 100 lg/mL streptomycin, and 100 U/mL penicillin and insulin 5 ng/mL (all Sigma-Aldrich). 
Chemicals
Activity based Probes Labelling
Activity of proteasome subunits after treatment was assessed using the recently developed set of subunit-selective activity based probes (ABP) that differentially visualises individual activities of b1, b2 and b5 subunits of the constitutive and immunoproteasome [19] .
Flow Cytometry
For determination of apoptosis, cells were exposed to the indicated drugs for 1 h, followed by removal of the drugs and subsequent incubation with 20 lM lopinavir or drug-free medium for 48 h. Cells were stained with the annexin V/propidium iodide Detection Kit (Biotool, Munich, Switzerland) according to the manufacturer's instructions. After, cells were analysed on a FACSCanto II TM (BD Biosciences, San Jose, CA, USA), data were analysed using FlowJo v10 Software (FlowJo Company, Ashland, OR, USA).
For cell cycle distribution, cells were exposed to the indicated drugs for 1 h, followed by removal of the drugs and subsequent incubation in drug-free medium for 48 h. Then, cells were incubated with RNAse A (Sigma-Aldrich) for 30 min and propidium iodide for 10 min (Sigma-Aldrich). Cells were analysed on FACSCanto II (BD Biosciences) and cell cycle distribution was evaluated using FACSDiva TM Software (BD Biosciences).
For measurement of intracellular reactive oxygen species (ROS) levels, cells were incubated with 10 lM 2 0 ,7 0 -dichlorofluorescin diacetate (H 2 DCFDA; Sigma-Aldrich) for 20 min at 37°C in the dark. Cells were washed, harvested and green fluorescence intensity was examined by FACSCanto II (BD Biosciences) and data were evaluated using FACSDiva Software (BD Biosciences).
ABCB1 functional assay was performed by MitoTracker TM Green FM staining (Thermo Fisher Scientific). Cells were pretreated with lopinavir or reserpine, a known ABCB1 inhibitor, for 2 h, then incubated with MitoTracker Green FM (Thermo Fisher Scientific) for 20 min at 37°C in the dark. Cells were washed, harvested and green fluorescence intensity was examined by FACSCanto II (BD Biosciences), data were evaluated using FlowJo v10 Software (FlowJo Company).
Statistical Evaluation
For kinetics of UPR activation, relative quantification of raw qRT-PCR data was performed using 2 ÀddCt method; data were normalised to housekeeping gene (GAPDH) and to time-point À30 min of 1 h pulse for all the treatments and combinations. The values obtained were then normalised to untreated cells at all the time-points, which served as a baseline. If not specified otherwise, for all experiments data are presented as the mean AE SD of three independent experiments, for flow cytometry data are presented as a mean of median of fluorescence AESD of at least three independent experiments. Group comparison for continuous data of qRT-PCR was done with two-way ANOVA with Bonferroni's posttest, for mean comparison of continuous data paired t-test or one-way ANOVA and Bonferroni's Multiple Comparison test was used. P values < 0.05 were considered as statistically significant in all analyses. Data were statistically analysed using GraphPad Prism version 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
Cytotoxic Activity of Proteasome Inhibitors and HIV-PIs on RCC Cell Lines and Primary Cells
We compared cytotoxic activity of the two most common proteasome inhibitors in clinical use, bortezomib and carfilzomib, in combination with increasing doses of the HIVPIs lopinavir and nelfinavir in RCC cell lines (i.e. Caki-2, A498, and MZ1774). Bortezomib and carfilzomib alone were cytotoxic only in very high concentrations difficult to reach clinically in vivo (Fig. 1A,B, Table 1A ,B). However, combination with 10 or 20 lM lopinavir or nelfinavir significantly decreased the IC 50 (half maximal inhibitory concentration) values of bortezomib and carfilzomib in all studied cell lines in a one log order of magnitude. Carfilzomib showed even stronger synergistic effect with HIV-PI, compared to bortezomib (IC 50 for carfilzomib alone and combined with 10 lM lopinavir or nelfinavir, respectively, for Caki-2: 4118, 229.8 and 287.3 nM; for A498: 572.6, 55.02 and 60.94 nM, for MZ1774: 1606, 129.1 and 102.3 nM) (Fig. 1A,B , Table 1A,B; Tables S3 and S4 ). Given this and the lower rate of neurotoxicity of carfilzomib in the clinic, we Table 2) .
Proteasome Inhibition and ABCB1 Efflux Inhibition
Proteasome inhibiting drugs all by design target the ratelimiting b5 active subunit of the proteasome and differ with respect to co-targeting the b1 and b2 proteolytic subunits. To elucidate the mechanism for the synergistic activity of carfilzomib and lopinavir in RCC, we directly measured the degree of proteasome inhibition by proteasome inhibiting drugs in the presence or absence of HIV-PI, using ABP in Caki-2 and A498 cell lines. Lopinavir alone at up to 20 lM did not affect proteasome function, whilst 40 nM bortezomib was sufficient to block the activity of the proteasomal b5 and partly b1 protease subunits, consistent with its known pharmacodynamics' profile. Surprisingly, neither carfilzomib, nor ixazomib provided meaningful inhibition of the b5 proteasome subunit activity in RCC cells (Fig. 2Ai,ii) . Carfilzomib 40 nM resulted in full inhibition of the b5 proteasome subunit activity only during co-treatment with lopinavir. We hypothesised that export of carfilzomib by transmembrane efflux pumps may limit its intracellular concentration and hence activity of carfilzomib in RCC. Lopinavir might interfere with such drug export, resulting in increased intracellular carfilzomib concentration and hence activity of the drug in RCC.
ABCB1 is a major drug efflux pump that is upregulated in RCC, and carfilzomib has been suggested to be a strong substrate of this pump [20] [21] [22] . We therefore evaluated ABCB1 expression in RCC cell lines and primary cells. ABCB1 was expressed at different levels in all RCC cell types studied (Fig. 2B) . High ABCB1 expression seemed to be inversely correlated with sensitivity towards carfilzomib, in particular in primary cells. To confirm the functional inhibition of drug efflux pumps by lopinavir, we performed efflux assays with MitoTracker Green FM, a well-known substrate of multidrug resistance (MDR)-type drug efflux membrane pumps [23] . These tests confirmed the functional modulation of ABCB1 in RCC cell lines and primary RCC cells by lopinavir (Fig. 2C) .
ROS Production and ER Stress Induction via UPR Activation Leading to Unresolved Stress and Apoptosis
As carfilzomib and lopinavir induced strong synergistic cytotoxicity against RCC cell lines and primary cells in vitro, we aimed to further elucidate the downstream mechanism of action of the drug combination. Production of ROS is a condition that is connected with ER stress and UPR activation [24] . We observed induction of ROS by lopinavir alone but not by carfilzomib at 1 h after treatment, and significant ROS induction was also seen with the combined treatment, which persisted for at least 24 h (Fig. 3A) .
Likewise, lopinavir, carfilzomib and combined treatment induced ER stress, as indicated by the activation of the UPR main pathways: IRE1/sXBP1, and ATF6, with the strongest and longest persisting effect seen with the combined treatment (Fig. 3B,C) . In addition, lopinavir strongly induced ATF4 transcription, reflecting the activation of the protein kinase (PKR)-like endoplasmic reticulum kinase (PERK)/ a-subunit of eukaryotic initiation factor 2 (eIF2a)/ATF4 pathway. In contrast to that, carfilzomib decreased ATF4 expression, but the decrease was counteracted by combination with lopinavir with the strongest transcriptional activation being found 8 h after treatment (Fig. 3D ). In addition, lopinavir alone and combined treatment induced expression of the ER chaperone BIP and triggered UPR-induced apoptotic signalling, as revealed by CHOP upregulation (Fig. 3E,F) .
Interestingly, lopinavir alone and the combination of lopinavir and carfilzomib significantly decreased the levels of BCL2 and increased BAX/BCL2 ratio sustainably (Fig. 4A,B) . Apoptosis induction was confirmed by the cleavage of caspase 3, caspase 7 and poly-[ADP-ribose]-polymerase (PARP), which showed the strongest induction in the combined treatment (Fig. 4C) .
Functional apoptosis was confirmed by annexin V/propidium iodide staining in >50% of Caki-2 cells treated with the combination of carfilzomib and lopinavir and also in the (Fig. 4D,E) . The cytotoxic effect was found to be mainly caused by the induction of apoptosis, as none of the treatments or their combination induced arrest of cell cycle (Fig. 4F ).
Discussion
Proteasome inhibitors have yielded durable clinical responses that dramatically improved survival of patients with multiple myeloma. A few exploratory preclinical and translational studies have investigated the potential of proteasome inhibition for the treatment of metastatic ccRCC and provided a sound rationale to advance the use of bortezomib in RCC treatment, especially as a part of combined therapies [25] [26] [27] . Although its use cannot be recommended in clinical routine, bortezomib showed an antitumour effect in vivo in individual patients previously [13] .
The second generation proteasome inhibitor carfilzomib has been developed mainly to overcome intrinsic or acquired resistance and off-target toxicity of bortezomib [14] . In a phase I/II clinical trial in solid tumours, including RCC, carfilzomib at a dose of 20/36 mg/m 2 was well tolerated, led to proteasome inhibition in blood, but demonstrated limited antitumour activity in patients with advanced solid tumours [28] . However, its combination with cytotoxic or targeted agents might lead to improved efficacy.
Carfilzomib resistance in multiple myeloma is partly caused by low degree of UPR activation and presence of drug efflux pumps, especially ABCB1 [29] . Most cases of ccRCC show mutations of the von Hippel-Lindau tumour suppressor gene, VHL, which prevents degradation of HIF-a transcription factors [30] . Stabilised HIF-1a accumulates and activates the hypoxia transcription programme, including upregulation of MDR markers or UPR pathway [31] . Indeed, RCC is characterised by high MDR proteins expression, especially ABCB1, which is one of the mechanisms of chemotherapy resistance in RCC [32, 33] . Previously it has been shown that verapamil, an ABCB1 inhibitor, enhanced cytotoxicity of vinca alkaloid (vinblastine) and alkylators (carboplatin) in RCC [34] . However, clinical trials with verapamil were affected by serious cardiac side-effects, which prevented its use as an ABCB1 inhibitor in clinical practice [35, 36] .
Recent data in myeloma suggest that nelfinavir and lopinavir are able to overcome ABCB1-mediated drug resistance in vitro [22] . In the present study, using the MitoTracker Green FM efflux assay we show that lopinavir potently decreases ABCB1 efflux in ccRCC cell lines and primary cells derived from ccRCC tumour samples, and thus facilitates higher intracellular concentration of carfilzomib, an ABCB1 substrate, allowing for stronger proteasome inhibition.
For the viability and ABP experiments we used in vitro settings of 1 h pulse treatment with carfilzomib, which reflects i.v. administration as performed in clinical practice. We observed that lopinavir reduces IC 50 value of carfilzomib in ccRCC cell lines and primary cells to 100 nM range, which is achievable in vivo [37] . In contrast to verapamil, the doses of HIV-PI that were shown to sufficiently decrease ABCB1 efflux in vitro (~10-15 lM) have been consistently reached and were tolerated well in a phase I trial combining nelfinavir with proteasome inhibitor bortezomib in haematological malignancies [17] . The combination of bortezomib and nelfinavir resulted in overall response rate of 65% in a multicenter phase II trial for proteasome inhibitor-refractory myeloma without severe renal toxicity [38] . Thus, our recent in vitro findings strongly support a clinical trial assessing combined treatment of second generation proteasome inhibitors and HIV-PIs in RCC.
Renal toxicity was addressed previously as a potential drawback of carfilzomib. Although acute renal failure occurred in 4.2% of patients undergoing carfilzomib treatment for myeloma in an integrated safety analysis [39] , carfilzomib proved to be safe in patients with myeloma with renal impairment, and was well tolerated and demonstrated promising efficacy [40] . Moreover, acute renal failure and tumour lysis syndrome, described within case reports of individual patients undergoing carfilzomib-based therapy, were well manageable if properly monitored [41, 42] .
HIV-PIs are generally well tolerated and in particular there is no associated renal toxicity of lopinavir. However, cautious use was recommended for lopinavir/ritonavir in patients with structural heart disease, conduction system abnormalities, ischaemic heart disease or cardiomyopathies [43] . Moreover, side-effect profiles of specific combinations of HIV-PIs and second generation proteasome inhibitors have not been evaluated, to date. Thus, a phase I/II assessment of such combinations in patients with mRCC will be mandatory to evaluate side-effects and dose regimens. Of note, the first generation proteasome inhibitor bortezomib at its full, maximum tolerated dose did not result in dose-limiting toxicities when combined with escalating doses of nelfinavir in a phase I trial in patients with advanced haematological malignancies, and did not result in unexpected safety signals in a phase II trial in patients with advanced multiple myeloma [17, 38] .
Hypoxia causes ER stress and leads to rapid activation of the UPR. UPR signalling during hypoxia is closely connected to tumour metabolism, autophagy, and ER homeostasis. Therefore, triggering of the UPR may be selectively toxic to hypoxic cells [33] . Further, ccRCC is characterised by evaluated by qRT-PCR. Data are presented as mean AE SD of three independent experiments in RCC cell lines. P < 0.05 is marked with *, P < 0.01 is marked with **, P < 0.001 is marked with ***.
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© 2017 The Authors BJU International © 2017 BJU International deregulated oxidative phosphorylation, high glutathione and cysteine/methionine metabolism pathways. High glutathione in ccRCC has been shown to correlate with disease aggressiveness [44] and as glutathione is a major antioxidant in the cell and supports proper protein folding in the ER, targeting ROS-buffering capacity could be exploited as a therapeutic strategy, especially in an aggressive subset of kidney cancer [45] .
It has been shown by others and us that the HIV-PI lopinavir potently induces ROS production and ER stress via c-Jun Nterminal kinase (JNK) and UPR activation in many different cell lines [46] [47] [48] . Here we show that apart from ABCB1 modulation in ccRCC, lopinavir alone strongly induces ROS production and the UPR by IRE1/XBP1 activation, ATF6 cleavage and ATF4/CHOP transcription. However, induction of the UPR alone was not sufficient to induce apoptosis, perhaps due to the parallel anti-apoptotic effect of HIV-PIs as well [49] . Carfilzomib alone triggered the UPR by induction of IRE1/XBP1 and ATF6 signalling. However, it significantly decreased ATF4/CHOP expression, suggesting specific activation of pro-survival UPR, which is further supported by unchanged levels of BCL2 and BAX/BCL2 ratio. Nevertheless, combined treatment was highly cytotoxic in ccRCC cell lines and primary cells, and the toxicity was predominantly caused by apoptosis, opposed to cell cycle inhibition, as shown by In summary, we demonstrate that the second generation proteasome inhibitor carfilzomib may offer a new therapeutic option for patients with mRCC. However, its use as a monotherapy might be limited due to ABCB1 overexpression by RCC cells. We identified lopinavir and nelfinavir as approved 'off-the-shelf' drugs that induce ROS, activate the UPR and reduce ABCB1 activity in RCC and therefore might overcome treatment resistance that has mostly been observed for monotherapy with first generation proteasome inhibition in RCC. Lopinavir and nelfinavir substantially increase the activity of carfilzomib in ccRCC cell lines and primary cells at therapeutically relevant drug concentrations. Our present findings provide a sound rationale to test the safety and activity of carfilzomib combined with HIV-PIs in patients with mRCC in a phase I/II clinical trial.
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